Fate Therapeutics Reports Third Quarter 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
Fate Therapeutics (FATE) ASH Abstracts 'Underappreciated' - BMO
November 2, 2017 7:58 AM EDTBMO Capital analyst Do Kim reiterated an Outperform rating and $7 price target on Fate Therapeutics (NASDAQ: FATE) saying SITC and ASH data could driver shares.
Kim believes initial ProTmune Phase I data, released in ASH abstracts, were underappreciated, as the early results... More
